A proposed class of Restasis buyers filed an antitrust suit last week in a Texas federal court against Allergan (NYSE:AGN), according to reports from Law360.
The suit accuses Allergan of blocking generics to its dry-eye drug using tactics like sham infringement suits and a controversial deal with a Native American tribe.
Get the full story at our sister site, Drug Delivery Business News.
The post Restasis buyers level antitrust lawsuit against Allergan appeared first on MassDevice.
from MassDevice http://ift.tt/2B1C8TJ
Cap comentari:
Publica un comentari a l'entrada